Showing 1 - 12 results of 12 for search 'Mehmet Ali Nahit Sendur', query time: 0.03s
Refine Results
-
1
-
2
-
3
Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer by Ayberk Bayramgil, Ahmet Bilici, Ali Murat Tatlı, Seda Kahraman, Yunus Emre Altintas, Fahri Akgul, Musa Barış Aykan, Jamshid Hamdard, Sema Sezgin Göksu, Mehmet Ali Nahit Şendur, Fatih Selçukbiricik, Ömer Fatih Ölmez
Published 2025-02-01Get full text
Article -
4
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncolog... by Musa Barış Aykan, Hatice Bölek, Emre Yekedüz, Elif Sertesen, Deniz Tural, Cengiz Karaçin, Mehmet Ali Nahit Şendur, Gökhan Uçar, Çağatay Arslan, Selver Işık, Saadet Sim, Özlem Nuray Sever, Bekir Hacıoğlu, Sema Sezgin Göksu, Mustafa Özgüroğlu, Nuri Karadurmuş, Yüksel Ürün
Published 2025-04-01Get full text
Article -
5
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium by Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Hilal Karakas, Selver Isık, Murad Guliyev, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yuksel Urun
Published 2025-05-01Get full text
Article -
6
“Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment? by Serkan Yaşar, Ahmet Kadıoğlu, Arif Akyildiz, Nadiye Sever, Mehmet Emin Büyükbayram, Mehmet Bilici, Elanur Karaman, Mehmet Uzun, Murat Bardakcı, Caglar Koseoglu, Irem Bilgetekin, Mehmet Cihan İçli, Alper Türkel, Zafer Arık, Murat Sarı, Tugba Yavuzsen, Mehmet Ali Nahit Sendur, İsmail Erturk, Mutlu Dogan
Published 2025-06-01Get full text
Article -
7
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma by Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Saadet Sim, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Cengiz Karacin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Emre Yekedüz, Yüksel Ürün
Published 2025-07-01Get full text
Article -
8
Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treate... by Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali
Published 2018-12-01Get full text
Article -
9
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) s... by Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, Bahadır Koylu, Shute Ailia Dae, Abdullah Sakin, Dilek Erdem, Mehmet Ali Nahit Sendur, Elif Senocak Tasci, Faysal Dane, Ali Osman Kaya, Musa Baris Aykan, Yakup Ergun, Sedat Biter, Omer Dizdar, Umut Disel, Fatih Selcukbiricik, Fatih Kose, Omer Fatih Olmez, Gokhan Demir, Suayib Yalcin, Ahmet Bilici
Published 2025-07-01Get full text
Article -
10
Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study by Furkan Ceylan, Selin Aktürk Esen, Olçun Ümit Ünal, Ferit Aslan, İlknur Deliktaş Onur, Öztürk Ateş, Erkut Demirciler, İlkay Tuğba Ünek, Ahmet Gülmez, Esra Özen Engin, Semra Taş, Gamze Gököz Doğu, Melih Şimşek, Hacı Mehmet Türk, Ali İnal, Gökhan Şahin, Haydar Çağatay Yüksel, Ateş Kutay Tenekeci, Mutlu Hızal, Mehmet Ali Nahit Şendur, Doğan Uncu
Published 2025-04-01Get full text
Article -
11
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study by Serhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, Cihan Erol, Fahriye Tugba Kos, Mehmet Ali Nahit Sendur, Yunus Emre Altıntas, Tugba Tuylu, Sedat Yildirim, Sedat Biter, Mehmet Mutlu Kıdı, Ertugrul Bayram, Nargiz Majidova, Ibrahim Vedat Bayoglu, Mehmetcan Atak, Kadriye Baskurt, Sinem Akbas, Ali Alkan, Ayberk Bayramgil, Ferit Aslan, Elif Sahin, Onur Yazdan Balcik, Ahmet Ziya Bayhan, Seray Saray, Erkan Arpaci, Yakup Ergun
Published 2024-11-01Get full text
Article -
12
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur
Published 2024-12-01Get full text
Article